Treatment of Congenital Hemophilia A and B

Publication Date: June 19, 2024
Last Updated: June 25, 2024

Hemophilia A Without Inhibitors

In individuals with severe and moderately-severe hemophilia A without inhibitors, the ISTH Hemophilia Guideline Panel recommends prophylaxis over episodic treatment of bleeding events.

(S, M )

Remarks

  • The use of prophylaxis has a large benefit in reducing the risk of bleeding with minimal adverse events.
  • Cost and access to prophylactic concentrates remain the main barriers for implementation of this recommendation.
  • Increased uptake and adherence to prophylaxis in disadvantaged populations may help reduce current health equity gaps.
  • This recommendation may apply to patients with hemophilia A with a severe bleeding phenotype even when they have factor VIII plasma levels ≥ 2 IU/dL.
620

Hemophilia A With Inhibitors

In individuals with severe hemophilia A with inhibitors, the ISTH Hemophilia Guideline Panel suggests prophylaxis over episodic treatment of bleeding events.

(C, L )
620

Overview

Title

Treatment of Congenital Hemophilia A and B

Authoring Organization

International Society on Thrombosis and Haemostasis